利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

28 records (took 0.028 seconds)

    ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY POLYPEPTIDES
    1.
    发明申请
    ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY POLYPEPTIDES 有权

    公开(公告)号：US20250066494A1

    公开(公告)日：2025-02-27

    申请号：US18948807

    申请日：2024-11-15

    Applicant: The General Hospital Corporation

    Inventor： Denise L. FAUSTMAN

    IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K47/68 ,  A61P31/06 ,  A61P31/18 ,  A61P35/00 ,  C12N5/071 ,  C12N7/00 ,  C12N15/86 ,  G01N33/543 ,  G01N33/58 ,  G01N33/68

    Abstract: Described are antagonistic TNFR2 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs) and/or myeloid-derived suppressor cells (MDSCs), to expand T effector cell populations or function, and to reduce the proliferation of, or directly kill, tumor cells, such as tumor cells that express TNFR2 antigen. The polypeptides, such as antibodies and antigen-binding fragments thereof, are TNFR2 antagonists, such as dominant TNFR2 antagonists. The polypeptides can be used to suppress the T-reg- or MDSC-mediated deactivation of tumor reactive T lymphocytes, expand populations of tumor-reactive cytotoxic T cells, and/or to directly kill TNFR2+ tumor cells. The antagonistic TNFR2 polypeptides described herein can be used to treat a wide variety of cancers and infectious diseases.

    AGONISTIC TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY POLYPEPTIDES
    2.
    发明申请
    AGONISTIC TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY POLYPEPTIDES 有权

    公开(公告)号：US20220002423A1

    公开(公告)日：2022-01-06

    申请号：US17294008

    申请日：2019-11-15

    Applicant: The General Hospital Corporation

    Inventor： Denise L. FAUSTMAN

    IPC: C07K16/28 ,  C07K16/30 ,  C12N15/86

    Abstract: Described are agonistic TNFR2 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to stimulate the proliferation of regulatory T cells (Treg cells) and/or myeloid-derived suppressor cells (MDSCs), as well as to inhibit the function of, reduce the proliferation of, and/or directly kill, T effector cells, such as CD8+ T effector cells. The polypeptides, such as antibodies and antigen-binding fragments thereof, of the disclosure can be used, for example, to suppress autoimmunity and inflammation, as well as to promote the protection, healing, preservation, and/or regeneration of a wide variety of tissues and organs, such as tissues and organs containing TNFR2+ cells.

    AGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR 2 ANTIBODIES
    4.
    发明申请
    AGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR 2 ANTIBODIES 审中-公开

    公开(公告)号：US20190135929A1

    公开(公告)日：2019-05-09

    申请号：US15755404

    申请日：2016-08-26

    Applicant: The General Hospital Corporation

    Inventor： Denise L. FAUSTMAN

    IPC: C07K16/28 ,  G01N33/68 ,  A61K38/19 ,  A61K39/395 ,  A61P37/06

    Abstract: The invention provides agonistic TNFR2 antibodies and antigen-binding fragments thereof and encompasses the use of these antibodies as therapeutics to promote the proliferation of regulatory T cells (T-reg) for the treatment of immunological diseases. Antibodies of the invention can be used to potentiate the T-reg-mediated deactivation of self- and allergen-reactive T- and B-eases. Antibodies and can thus be used to treat a wide variety of indications, including autoimmune diseases, allergic reactions, asthma, graft-versus-host disease, and allograft rejection, among others.

    ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES
    8.
    发明申请
    ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES 有权

    公开(公告)号：US20210317221A1

    公开(公告)日：2021-10-14

    申请号：US17150686

    申请日：2021-01-15

    Applicant: The General Hospital Corporation

    Inventor： Denise L. FAUSTMAN

    IPC: C07K16/28 ,  A61K39/395

    Abstract: Antagonistic TNFR superfamily polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs). For example, antibodies of the invention include antagonistic TNER2 antibodies and antigen-binding fragments thereof, and can be used to suppress the T-reg-mediated deactivation of tumor reactive T-lymphocytes, as well as to treat a wide variety of cancers and infectious diseases.

    TUMOR NECROSIS FACTOR SUPERFAMILY AND TNF-LIKE LIGAND MUTEINS AND METHODS OF PREPARING AND USING THE SAME
    10.
    发明申请
    TUMOR NECROSIS FACTOR SUPERFAMILY AND TNF-LIKE LIGAND MUTEINS AND METHODS OF PREPARING AND USING THE SAME 有权

    公开(公告)号：US20220098263A1

    公开(公告)日：2022-03-31

    申请号：US17468375

    申请日：2021-09-27

    Applicant: The General Hospital Corporation

    Inventor： Denise L. FAUSTMAN ,  Eva VANAMEE

    IPC: C07K14/525 ,  A61K38/19

    Abstract: The invention features homo-multimers, e.g., homo-trimers, of TNFSF or TNF-like ligand muteins in which each TNFSF ligand or TNF-like ligand mutein monomer contains at least one cysteine residue substitution or insertion that promotes the formation of a disulfide bond with a cysteine residue on a neighboring TNFSF or TNF-like ligand mutein monomer. The invention features methods of producing such TNFSF and TNF-like ligand muteins, pharmaceutical compositions containing such muteins, and methods of using such muteins in cancer immunotherapy, in treating autoimmune and neurological diseases, and in reducing or eliminating the complications and risks of rejection in organ transplantation or tissue or organ repair or regeneration.

Patent Agency Ranking